A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Catridecacog (Primary)
- Indications Factor XIII deficiency
- Focus Pharmacokinetics; Registrational
- Acronyms Mentor-4
- Sponsors Novo Nordisk
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 03 Jul 2014 New trial record